DAVID HARRIS: Open Payments
NPI 1497799951 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,649 in 123 payments from 18 companies in 2025. Trend: 2023 $1,834 · 2024 $2,779 · 2025 $2,649
Food & beverage: $2,570Education: $80
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $355 |
| Otsuka America Pharmaceutical, Inc. | 16 | $343 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $290 |
| Neurocrine BioSciences, Inc. | 14 | $266 |
| E.R. Squibb & Sons, L.L.C. | 12 | $265 |
| Janssen Pharmaceuticals, Inc | 10 | $250 |
| Axsome Therapeutics, Inc. | 5 | $210 |
| Alkermes, Inc. | 7 | $162 |
| Luye Pharma (USA) Ltd. | 6 | $102 |
| Collegium Pharmaceutical, Inc. | 5 | $100 |
Products named: CAPLYTA, INGREZZA, COBENFY, INVEGA SUSTENNA, Auvelity, ARISTADA, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across MI — which companies pay providers there.
